孫艷霞

DOI：10.16662/j.cnki.1674-0742.2017.09.121

[摘要] 目的 探討吸入布地奈德混懸液對毛細支氣管炎后喘息的影響。方法 方便收集2014年5月—2015年12月期間在該院兒科接受治療的200例毛細支氣管炎嬰幼患兒， 根據(jù)患兒入院序號，單號納入觀察組100例，雙號納入常規(guī)組100例。常規(guī)組采用常規(guī)治療。觀察組則在常規(guī)組基礎上加用布地奈德混懸液霧化吸入治療。觀察兩組患兒治療前后血清白細胞介素-4（IL-4）、IL-8及腫瘤壞死因子-α（TNF-α）水平的變化及臨床療效，并記錄患兒隨訪1年期間是否發(fā)生喘息及喘息次數(shù)。 結果 觀察組的治愈率、總有效率（48.0%、97.0%）明顯高于常規(guī)組（34.0%、89.0%）（P<0.05）。治療后，觀察組患兒血清IL-4、IL-8、TNF-α水平分別為（4.3±1.2）、（40.7±9.3）、（71.4±19.8）pg/mL，明顯低于常規(guī)組的（5.3±1.3）、（46.3±9.4）、（81.2±21.6）pg/mL。觀察組隨訪期間喘息發(fā)生率、平均年喘息次數(shù)分別為17.0%、（2.7±0.3）次明顯低于常規(guī)組的37.0%和（3.5±0.4）次（P<0.05）。結論 布地奈德混懸液霧化吸入治療毛細支氣管炎患兒喘息可提高臨床療效，降低藥物使用量，減輕炎癥細胞因子的釋放，降低病后1年內的喘息率，且起效快、作用強， 值得臨床推廣應用。

[關鍵詞] 布地奈德混懸液；毛細支氣管炎；喘息

[中圖分類號] R725.6 [文獻標識碼] A [文章編號] 1674-0742（2017）03（c）-0121-03

Effect of Udesonide on Bronchial Asthma by Inhaling on the Wheezing of Capillary Bronchitis

SUN Yan-xia

Department of Pediatrics， Guanxian Central Hospital， Guanxian， Shandong Province， 252500 China

[Abstract] Objective To discuss the effect of udesonide on Bronchial Asthma by Inhaling on the Wheezing of capillary bronchitis. Methods Convenient selection 200 cases of children with capillary bronchitis treated in our hospital from May 2014 to December 2015 were collected and divided into two groups with 100 cases in each according to the admission order， the routine group adopted the routine treatment， while the observation group added the Bronchial Asthma by Inhaling on the basis of the routine group， and the serum IL-4， IL-8 and TNF-α level changes and clinical curative effect of the two groups were observed and whether Wheezing occurred to children or not and wheezing frequency of children during one-year follow-up were recorded. Results The cure rate and total effective rate in the observation group were obviously higher than those in the routine group（48.0%， 97.0% vs 34.0%， 89.0%）（P<0.05）， after treatment， the serum IL-4，IL-8，TNF-α levels in the observation group were obviously higher than those in the routine group[（4.3±1.2）， （40.7±9.3），（71.4±19.8）pg/mL vs （5.3±1.3），（46.3±9.4），（81.2±21.6）pg/mL]， and the incidence rate of wheezing during follow-up and average wheezing frequency in the observation group were obviously lower than those in the routine group[17.0%， （2.7±0.3） vs 37.0%， （3.5±0.4）]（P<0.05）. Conclusion The inhalation treatment of bronchial asthma in treatment of wheezing of capillary bronchitis can improve the clinical curative effect， reduce the drug dosage， relieve the release of inflammatory cell factors and reduce the wheezing rate in 1 year after disease with quicker and stronger effect， which is worth clinical promotion and application.